Company intelligence / Profile preview

Aloe Therapeutics

Germantown, Maryland, United Statesaloetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing a localized immunotherapy that induces transplant rejection immune response at tumor sites to make checkpoint immunotherapy more effective. AIM-001 is designed to turn "cold" tumors "hot" by triggering an influx of immune cells in the tumor microenvironment.

Therapeutic areas: Oncology
Modalities: Cell-based therapyImmunotherapy
Industry: Biotech

Drug pipeline

1 asset

AIM-001

Pre-clinical

Indications: Solid tumors, Renal cancer, Metastatic cancer

Beyond the preview

Go deeper on Aloe Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aloe Therapeutics.

Explore the full profile